Automated devices, systems, and methods for the fabrication of tissue

a tissue and automatic technology, applied in the field of health care industry, can solve the problems of low rate of new therapeutic discovery, high cost of drug discovery, and long process, and achieve the effects of reducing the urgent need for tissues, reducing the number and quality of innovative, and facilitating the application of regenerative medicin

Inactive Publication Date: 2015-02-05
ORGANOVO
View PDF6 Cites 127 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0004]There is a need for tools and techniques that facilitate application of regenerative medicine and tissue engineering technologies to relieving the urgent need for tissues and organs. There is also a need for tools and techniques that substantially increase the number and quality of innovative, cost-effective new medicines, without incurring unsustainable R&D costs. The inventors describe herein improvements to devices, systems, and methods for fabricatin

Problems solved by technology

A number of pressing problems confront the healthcare industry.
Additionally, the research and development cost of a new pharmaceutical compound is approximately $1.8 billion.
Despi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Automated devices, systems, and methods for the fabrication of tissue
  • Automated devices, systems, and methods for the fabrication of tissue
  • Automated devices, systems, and methods for the fabrication of tissue

Examples

Experimental program
Comparison scheme
Effect test

example 1

HASMC-HAEC Mixed Cellular Cylinders

Cell Culture

[0291]Smooth Muscle Cells:

[0292]Primary human aortic smooth muscle cells (HASMC) were maintained and expanded in low glucose Dulbecco's modified eagle medium (DMEM; Invitrogen Corp., Carlsbad, Calif.) supplemented with 10% fetal bovine serum (FBS), 100 U / ml Penicillin, 0.1 mg / ml streptomycin, 0.25 μg / ml of amphotericin B, 0.01M of HEPES (all from Invitrogen Corp., Carlsbad, Calif.), 50 mg / L of proline, 50 mg / L of glycine, 20 mg / L of alanine, 50 mg / L of ascorbic acid, and 3 μg / L of CuSO4 (all from Sigma, St. Louis, Mo.) at 37° C. and 5% CO2. Confluent cultures of HASMCs between passage 4 and 8 were used in all studies.

[0293]Endothelial Cells:

[0294]Primary human aortic endothelial cells (HAEC) were maintained and expanded in Medium 200 supplemented with 2% FBS, 1 μg / ml of hydrocortisone, 10 ng / ml of human epidermal growth factor, 3 ng / ml of basic fibroblast growth factor, 10 μg / ml of heparin, 100 U / ml Penicillin, 0.1 mg / ml streptomycin, a...

example 2

Multi-Layered Vascular Tubes

Cell Culture

[0301]Smooth Muscle Cells:

[0302]Primary human aortic smooth muscle cells (HASMC; GIBCO) were maintained and expanded in low glucose Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U / ml Penicillin, 0.1 mg / ml streptomycin, 0.25 μg / ml of amphotericin B, 0.01M of HEPES (all from Invitrogen Corp., Carlsbad, Calif.), 50 mg / L of proline, 50 mg / L of glycine, 20 mg / L of alanine, 50 mg / L of ascorbic acid, and 3 μg / L of CuSO4 (all from Sigma, St. Louis, Mo.) at 37° C. and 5% CO2. Confluent cultures of HASMC between passage 4 and 8 were used in all studies.

[0303]Endothelial Cells:

[0304]Primary human aortic endothelial cells (HAEC) were maintained and expanded in Medium 200 supplemented with 2% FBS, 1 μg / ml of hydrocortisone, 10 ng / ml of human epidermal growth factor, 3 ng / ml of basic fibroblast growth factor, 10 μg / ml of heparin, 100 U / ml Penicillin, 0.1 mg / ml streptomycin, and 0.25 μg / ml of amphotericin B (all ...

example 3

Bioprinter

[0320]A bioprinter was assembled. The bioprinter contained a printer head having a collet chuck grip for holding a cartridge, and a piston for dispensing the contents of the cartridge. The cartridges used were glass microcapillary tubes having a length of 75-85 mm. A new capillary tube was loaded each time bio-ink or support material was required.

[0321]In order to print structures, a dispense position repeatability of ±20 μm was required for the duration of the printing process, i.e., when new capillaries were loaded into the printer head. In order to maintain repeatability of all loaded capillary tubes relative to the same point in the x-, y-, and z-directions, the bioprinter contained a laser calibration system for calibrating the position of the microcapillary tube. The laser calibration system calibrated the position of all capillary tips to a common reference location. All printing moves were made relative to this reference position.

[0322]All three axes (x-, y-, and z...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Flow rateaaaaaaaaaa
Heightaaaaaaaaaa
Login to view more

Abstract

Described herein are improvements to bioprinting technology that facilitate automation of tissue and organ fabrication processes.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Application Ser. No. 61 / 860,644, filed Jul. 31, 2013, which is hereby incorporated by reference in its entirety.BACKGROUND OF INVENTION[0002]A number of pressing problems confront the healthcare industry. As of June 2013, there were approximately 118,000 patients registered by United Network for Organ Sharing (UNOS) as needing an organ transplant. Between January and March 2013, only 6,891 transplants were performed. Each year more patients are added to the UNOS list than transplants are performed, resulting in a net increase in the number of patients waiting for a transplant. For example, as of 2011, over 15,000 people were registered as needing a liver graft / transplant; however only about 5,800 liver transplants were performed that year. In 2010, the median wait time for a liver was over 12 months.[0003]Additionally, the research and development cost of a new pharmaceutical compound is approxi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): B29C67/00B05D1/40
CPCB05D1/40B29C67/0088B29L2031/7532B41J2/04C12M21/08C12M33/00B29C64/112A61F2240/00B29C64/393B29C64/182B29C64/106B33Y70/00B41J3/407C12M41/00C12M25/00C12M33/12B33Y30/00A61F2/00B33Y50/02B29K2995/0056B33Y10/00B33Y80/00B29K2033/08B29K2071/02B29L2031/40G05B19/27G05B2219/49023
Inventor MURPHY, KEITHPENTONEY, JR., STEPHENLIN, FRANKGORGEN, VIVIANPLATT, CLAYRAPOPORT, HARRY SCOTTDAMLE, SAMIRJOSHI, VAIDEHIPRESNELL, SHARON C.
Owner ORGANOVO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap